- Home
- OABI vs TVRD Comparison
OABI vs TVRD Comparison
Compare OABI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- TVRD
- Stock Information
- Founded
- OABI 2012
- TVRD 2017
- Country
- OABI United States
- TVRD United States
- Employees
- OABI N/A
- TVRD N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- TVRD Health Care
- Exchange
- OABI Nasdaq
- TVRD Nasdaq
- Market Cap
- OABI 236.1M
- TVRD 246.5M
- IPO Year
- OABI N/A
- TVRD N/A
- Fundamental
- Price
- OABI $1.94
- TVRD $25.47
- Analyst Decision
- OABI Strong Buy
- TVRD Strong Buy
- Analyst Count
- OABI 3
- TVRD 5
- Target Price
- OABI $7.00
- TVRD $59.20
- AVG Volume (30 Days)
- OABI 643.9K
- TVRD 88.8K
- Earning Date
- OABI 08-06-2025
- TVRD 08-21-2025
- Dividend Yield
- OABI N/A
- TVRD N/A
- EPS Growth
- OABI N/A
- TVRD N/A
- EPS
- OABI N/A
- TVRD N/A
- Revenue
- OABI $26,744,000.00
- TVRD N/A
- Revenue This Year
- OABI N/A
- TVRD N/A
- Revenue Next Year
- OABI $45.02
- TVRD N/A
- P/E Ratio
- OABI N/A
- TVRD N/A
- Revenue Growth
- OABI 27.07
- TVRD N/A
- 52 Week Low
- OABI $1.22
- TVRD $8.13
- 52 Week High
- OABI $4.96
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- OABI 57.48
- TVRD N/A
- Support Level
- OABI $1.93
- TVRD N/A
- Resistance Level
- OABI $2.11
- TVRD N/A
- Average True Range (ATR)
- OABI 0.14
- TVRD 0.00
- MACD
- OABI -0.00
- TVRD 0.00
- Stochastic Oscillator
- OABI 47.24
- TVRD 0.00
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.